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Abstract
Background: Several modalities are used for the treatment of varicose veins. Open surgical treatment with ligation
and stripping of the saphenous vein has been the standard of care for many years. Endovenous thermal ablation
has been shown to be a safe and effective alternative with high, long-term, target-vein closure rates. Despite this,
there is the possibility of thermal injury to surrounding structures. The recently introduced cyanoacrylate closure is
also considered to be a good alternative and the risk of injury to surrounding structures is minimal. The purpose of
this study is to demonstrate the non-inferiority of cyanoacrylate closure with the VenaSeal™ closure system
compared to surgical stripping in terms of clinical outcomes for the treatment of incompetent great saphenous
veins.
Methods/design: This is an open-label, multicenter, prospective, randomized controlled trial evaluating the non-
inferior clinical outcomes of cyanoacrylate closure compared to surgical stripping for the treatment of incompetent
saphenous veins. After baseline measurements, participants will be randomly allocated into either the cyanoacrylate
closure group or the surgical-stripping group. The primary endpoint of the study is the complete closure rate of the
target vein in the cyanoacrylate closure group, and the absence of venous reflux or residual venous tissue after
surgical stripping in the surgical-stripping group. These endpoints will be measured by Doppler ultrasound
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performed by qualified vascular technologists or investigators at 3 months after treatment. Secondary outcomes
include perioperative pain, postoperative ecchymosis, clinical assessment (including general and disease-specific
quality of life evaluations), complete closure rate, and absence of venous reflux or residual venous tissue at the 12-
and 24-month follow-ups, as well as all adverse event rates during the 24-month follow-up period.
Discussion: This multicenter randomized controlled trial is designed to show non-inferiority in terms of complete
closure rate of cyanoacrylate compared to surgical stripping for the treatment of incompetent saphenous veins.
Trial registration: Clinical Research Information Service (CRIS), ID: KCT0003203. Registered on 20 September 2018.
Keywords: Varicose vein, Stripping, Endovenous ablation, Occlusion, Quality of life
Background
Varicose veins are highly prevalent, and in Western
countries, an estimated 23% of adults have varicose veins
and 6% have advanced chronic venous disease, including
skin changes and healed or active venous ulcers [1]. Al-
though several modalities are used in the treatment of
varicose veins, open surgical treatment with ligation and
stripping of the saphenous vein, combined with excision
of large varicosities, has traditionally been the standard
of care for many years. However, surgical stripping is
usually associated with a 2- to 3-week recovery period
until normal activity can be resumed.
In the 1990s, however, a notable revolution occurred
in the treatment of varicose veins, which was introduced
by the introduction of minimally invasive endovenous
techniques. Endovenous thermal ablation by radiofre-
quency ablation (RFA) or endovenous laser ablation
(EVLA) is a safe and effective alternative with good
long-term target-vein closure rates [2]. The results of
these endovenous thermal ablations, even in some of the
randomized clinical trials compared to previous surgical
methods, have consistently been excellent [3, 4]. For this
reason, thermal ablation as the first-line treatment of
truncal-vein incompetence is now widely accepted and
frequently used in clinical practice. However, there is a
possibility of thermal injury of the surrounding struc-
tures such as nerve injury and skin burns. The use of tu-
mescent anesthesia is a prerequisite in order to prevent
thermal injury; however, this is time-consuming and has
side effects such as pain, ecchymosis, and hematoma for-
mation [5, 6].
The recently introduced cyanoacrylate closure method
is a good alternative since it does not result in thermal
injury; thus, there is no need for the use of tumescent
anesthesia [7–9], the so-called non-thermal, non-
tumescent endovenous technique. Therefore, this
method is considered to have more advantages for a pa-
tient’s perioperative experience with excellent outcome
than conventional surgery. However, to the best of our
knowledge, the papers published so far report only the
excellent results of the cyanoacrylate closure method
alone, a comparison of outcomes with thermal ablation,
or a comparison of quality of life only. The purpose and
the importance of this study is to demonstrate the non-
inferior clinical outcomes of cyanoacrylate closure with
the VenaSeal™ closure system compared directly to sur-
gical stripping for the treatment of incompetent saphe-
nous veins. Furthermore, this study could confirm the
complete closure rate of cyanoacrylate closure in the
long-term period in a multicenter setting, which remains
unclear in the long-term.
Methods/design
Study objectives, hypothesis, and design
This is an open-label, multicenter, prospective, ran-
domized controlled trial that will evaluate whether
the clinical outcomes after cyanoacrylate closure are
non-inferior to surgical stripping for the treatment
of incompetent saphenous veins (Clinical Research
Information Service (CRIS), KCT0003203). After
baseline measurements, participants will be randomly
allocated into the cyanoacrylate closure group or the
surgical-stripping group. Participating centers are in
Korea of which Kyung Hee University Hospital at
Gangdong, Seoul National University Bundang Hos-
pital, Wonkwang University Hospital, Yeungnam
University Medical Center, and Seoul Metropolitan
Government-Seoul National University Boramae
Medical Center and will participate in patient re-
cruitment and data collection.
Study population and eligibility
Patients will be eligible for inclusion in the study if they
require treatment for incompetent saphenous veins and
have one or more of the following symptoms related to
the incompetent saphenous vein: aching, throbbing,
heaviness, fatigue, pruritus, night cramps, restlessness,
discomfort, or swelling. To be eligible for randomization,
patients must have identifiable reflux in the great saphe-
nous vein (GSV) for greater than 0.5 s after distal com-
pression and release or Valsalva’s maneuver in the
standing or reverse Trendelenburg position. Patients
must also have a Clinical, Etiologic, Anatomic, and Path-
ophysiologic (CEAP) classification score of C2 through
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C5. Other inclusion and exclusion criteria are listed in
Table 1.
Intervention and assessment schedule
All patients with symptomatic incompetent GSVs will be
treated by either cyanoacrylate closure or surgical strip-
ping and followed up for a total of 24 months after treat-
ment. A brief flowchart of the study is presented in
Table 2.
Cyanoacrylate closure with the VenaSeal™ closure system
(Medtronic, Minneapolis, MN, USA)
Under all types of anesthesia (general, spinal, regional
block, or local anesthesia), the VenaSeal™ closure system
is used as per the instructions for use by the manufac-
turer. In brief, the target vein is accessed and a guidewire
is inserted. A 5-Fr introducer sheath/catheter is ad-
vanced to the saphenofemoral junction. The catheter tip
is positioned 5.0 cm caudal to the junction. With prox-
imal saphenous vein compression using the ultrasound
probe, two injections of approximately 0.10 mL cyano-
acrylate glue are given 1 cm apart at this location,
followed by 3 min of local manual compression. A
second single injection is given 3 cm distally after prox-
imal vein compression using the ultrasound probe, and
manual compression is performed for 30 s. This latter
sequence is repeated throughout the entire length of the
target vein to be treated. After completion, the sheath/
catheter is removed, and compression is applied to the
catheter entry site until hemostasis is achieved. Target-
vein occlusion is confirmed by duplex ultrasound.
Surgical stripping
All types of anesthesia (general, spinal, regional block, or
local anesthesia) can be used. Surgical stripping is per-
formed with a proper incision in the groin, with division
and ligation of the saphenous vein and division of all
tributaries. The saphenous vein is then removed using a
stripper.
Adjunctive procedures
Adjunctive procedures, such as phlebectomy of tributar-
ies or sclerotherapy, can be performed at the discretion
of the operator.
Follow-up
Outcomes are recorded at 3 days and 1, 3, 6, 12, and 24
months after treatment (Table 2). The participants
should return to the clinic 3 days after treatment and
clinical information is collected. This includes the partic-
ipants’ reporting of perioperative pain using a Visual
Analog Scale (VAS); the investigator’s assessment of the
presence of ecchymosis, rated using a 0- to 5-point scale
(0, none; 1, involving < 25% of the treatment area; 2, 25–
50%; 3, 50–75%; 4, 75–100%; 5, extension above or
below the treatment segment); and the result of duplex
ultrasound. The participants should also return 1 month,
3 months, 6 months, 12 months, and 24 months after
treatment in order for clinical information to be col-
lected; this includes the Venous Clinical Severity Score
(VCSS) and the evaluation of the participants’ quality of
life assessed by the Aberdeen Varicose Vein Question-
naire (AVVQ) and the EuroQoL Five Dimensions Ques-
tionnaire (EQ-5D). Duplex ultrasound follow-up is also
performed at 3 months, 12 months, and 24 months.
Other health problems and all adverse events are moni-
tored at each study visit. The trial follow-up will con-
tinue until 24 months after index treatment.
Outcome measures
The primary endpoint of the study is to evaluate the
complete closure of the target vein; this is defined as
vein closure along the entire treated vein segment with
no discrete segments of patency exceeding 5 cm after
cyanoacrylate closure, and the absence of venous reflux
or residual venous tissue after surgical stripping. These
endpoints will be measured by duplex ultrasound
Table 1 Study eligibility criteria
Inclusion criteria
Aged between 18 and 80 years
Reflux in the great saphenous vein of > 0.5 s
Diameter of the saphenous vein between 2 and 20 mm (standing
position)
One or more of the symptoms related to the incompetent saphenous
vein
CEAP classification of C2 through C5
Exclusion criteria
Previous treatment in the targeted vein segment
Tortuous vein in which the delivery catheter cannot be inserted
Aneurysm of target-vein segment of > 20 mm




Regular or current use of systemic anticoagulation
Previous deep vein thrombosis/pulmonary embolism or active acute
superficial thrombophlebitis
Unable to comply with the schedule and protocol evaluations
Unable to ambulate
Unable to provide informed consent
Currently pregnant or breastfeeding
Known sensitivity to cyanoacrylate adhesives
Participation in another clinical study that did not reach the primary
endpoint within 30 days prior to enrollment
CEAP Clinical, Etiologic, Anatomic, and Pathophysiologic
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performed by a qualified vascular technologist or investi-
gator at 3 months after treatment. The secondary out-
comes include perioperative pain, postoperative
ecchymosis, VCSS score, AVVQ, and EQ-5D at each
scheduled follow-up visit; all adverse events during the
24-month follow-up period; and the complete closure
rate and absence of venous reflux or residual venous tis-
sue at the 12- and 24-month follow-ups.
Adverse events
Adverse events in clinical trials refer to all adverse
events observed in the study subjects and do not ne-
cessarily have a causal relationship with treatment.
The recording of serious adverse events (SAEs) will
conform to the Good Clinical Practice standards and
the Research Governance Framework 2005. The ana-
lysis of safety-related data will be performed with re-
spect to the frequency of SAEs, including all-cause
death, life-threatening events, need for hospitalization,
need to extend hospital stay, and permanent signifi-
cant function impairment. SAEs must be reported by
the attending physician to the principal investigator
within 24 h after the SAE becomes known.
Statistical considerations
The purpose of this study is to evaluate the non-
inferiority of cyanoacrylate closure to surgical stripping
in the treatment of incompetent saphenous veins. A
sample size of 73 in each group will achieve 80% power
to detect a non-inferiority margin difference between the
group proportions of 96% in the cyanoacrylate group
and 93% in the surgical-stripping group, assuming a
dropout rate of 20%. Randomization will be performed
by an independent statistical core at Kyung Hee Univer-
sity Hospital. The allocation of treatment will be done
via a web-based randomization system, which returns
the treatment group after the input of a participant’s
study ID and inclusion/exclusion criteria.
The participants’ characteristics will be summarized
using mean and standard deviation for continuous vari-
ables and frequency and percentage for categorical vari-
ables. A two-sided 95% confidence interval for a
difference in occlusion rate between the two treatment
groups will be calculated; then, whether the upper limit
of confidence interval falls within the pre-determined
margin of non-inferiority will be evaluated in order to
prove the non-inferiority of cyanoacrylate closure to sur-
gical stripping. Among the secondary outcomes, adverse
events will be analyzed using chi-squared tests or Fish-
er’s exact tests as appropriate. SAEs will be compared
using log-rank tests and survival curves constructed
using Kaplan-Meier methods.
Significance tests will be two-sided. A P value of <
0.05, according to SPSS, will be considered to indicate a
statistically significant difference between the groups.
SPSS software version 22 (IBM, Armonk, NY, USA) will
be used for data analysis.
Discussion
Since the 1990s, with the advent of minimal invasive
modalities for patient treatment having became major is-
sues in medicine, many new modalities have also been
developed and introduced into the area of varicose vein
treatment.
The turning point in the treatment of varicose veins
was the introduction of endovenous treatment tech-
niques. The initial modalities of these endovenous treat-
ments were mainly heat-based treatments, and
constantly report anatomical success rates of over 90%
[3, 4, 10–12]. In addition to these good treatment re-
sults, the greatest advantage of endovenous thermal ab-
lation is that it has less post-procedural pain and fewer
related complications, which shortens the time to return
Table 2 Study protocol items of the trial
Study period
Screening Procedure 3 days 1 month 3 months 6 months 12months 24 months
Outpatient visit √ √ √ √ √ √ √
Physical examination √ √ √ √ √ √ √
Duplex examination √ √ √ √ √
Inclusion criteria √
Randomization √
VCSS √ √ √ √ √ √
Quality of life score – AVVQ √ √ √ √ √ √
VAS pain score √ √ √
Ecchymosis √ √
Other adverse events √ √ √ √ √ √ √
VCSS Venous Clinical Severity Score, AVVQ Aberdeen Varicose Vein Questionnaire, VAS Visual Analog Scale
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to normal activities. However, pain-related factors that
benefit from endovenous thermal ablation can be further
maximized by the introduction of non-thermal ablation,
which is considered the second generation of endove-
nous treatment.
The aim of the present randomized trial is two-
fold. First, it aims to compare anatomical and clin-
ical success at 2 years after cyanoacrylate closure
(CAC), with conventional surgery. Several random-
ized clinical trials have compared CAC with RFA,
EVLA, and foam sclerosis but not with conventional
surgery [13, 14] since the first report of human use
of CAC for the treatment of saphenous-vein incom-
petent [15]. Therefore, the authors propose the need
for a direct comparison of the outcome between
CAC and conventional surgery.
Second, the trial aims to demonstrate that CAC is
associated with a significant reduction in post-
procedural pain. Pain after endovenous thermal abla-
tion is considerable and probably under-reported. Re-
cent reports have reported less pain after RFA than
EVLA [16, 17].
According to a recent trial, mechanochemical
endovenous ablation reported better results than
RFA for pain. Based on these results, non-thermal
methods may be expected to have better results in
secondary treatment outcomes than thermal [18].
Therefore, we have assumed that CAC could be
regarded as a modality to maximize the patient’s
comfort in relation to these pains. To further
strengthen this hypothesis, the trial was designed
using a non-inferiority principle.
In conclusion, the CASS trial is multicenter ran-
domized controlled trial that aims to show a similar
anatomical and clinical success rate, with a reduction
in post-procedural pain after CAC, compared with
conventional surgery.
Trial status
Recruitment is ongoing with protocol version 1.3 (IRB
No. KHNMC 2018–03–030-005). The date of enroll-
ment of the first participant to the trial was 12 April
2018, and the approximate date of completion of recruit-
ment will be 29 February 2020.
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